Full Press Release Details
AVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY.
REGN
AVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY
Key Takeaway: AVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY